Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdictEli Lilly’s cancer drug Cyramza has inched closer to a new indication in first-line non-small cell lung cancer Share XLilly’s Cyramza closer to first-line lung cancer use after ODAC verdicthttps://pharmaphorum.com/news/lilly-closes-on-first-line-lung-cancer-use-after-odac-verdict/
New drugs boost Eli Lilly, ahead of animal health IPOEli Lilly closed the second quarter with substantial revenue increase thanks to a strong performance from a group Share XNew drugs boost Eli Lilly, ahead of animal health IPOhttps://pharmaphorum.com/news/lilly-charges-revenue-increase/
